Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced the closing of a registered direct offering priced at-the-market under Nasdaq rules, raising approximately $3.5 million in gross proceeds. The transaction, which closed on December 16, 2025, involved the sale of 2,661,600 shares of common stock at $1.315 per share. In a concurrent private placement, the company issued unregistered warrants to purchase up to an equal number of shares, with an exercise price of $1.19 per share and a five-year term from the effective date of the resale registration statement.
H.C. Wainwright & Co. served as the exclusive placement agent. After deducting fees and expenses, Lexaria intends to use the net proceeds to advance its research and development efforts, fund working capital, and for general corporate purposes. The offering was conducted under a shelf registration statement on Form S-3 (File No. 333-284407), declared effective by the SEC on January 30, 2025. The prospectus supplement and accompanying prospectus are available on the SEC's website at www.sec.gov.
Lexaria's DehydraTECH platform is a patented drug delivery formulation technology designed to improve the oral delivery of a wide range of drugs. According to the company, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption, reduce side effects, and enhance delivery across the blood-brain barrier. The company holds 56 granted patents and additional pending patents worldwide. The latest capital infusion is expected to support further validation of this technology through research and development initiatives.
The warrants issued in the private placement were offered under Section 4(a)(2) of the Securities Act and Regulation D, and have not been registered under the Securities Act or state securities laws. As such, they may only be offered or sold pursuant to an effective registration statement or an applicable exemption. This move is typical for companies seeking to raise capital while minimizing dilution, as the warrants provide investors with potential upside without immediate share issuance.
The closing of this offering comes at a critical time for Lexaria as it seeks to commercialize its DehydraTECH platform. The company has been actively conducting research to demonstrate the technology's efficacy in improving drug delivery, particularly for central nervous system disorders and other therapeutic areas. With the new funds, Lexaria can accelerate its research timeline and potentially bring its technology to broader applications.
Investors should note that the company’s forward-looking statements involve risks and uncertainties, including market conditions, regulatory approvals, and the outcome of research studies. Lexaria disclaims any obligation to update these statements. For more information about the company and its technology, visit www.lexariabioscience.com.
The successful closing of this offering underscores investor confidence in Lexaria's drug delivery platform and its potential to address unmet medical needs. As the company deploys the capital, stakeholders will be watching for progress in its R&D pipeline and any subsequent milestones that could drive value.
